VC firms
We invest in the brightest minds in life sciences. We are a global investment platform focused on growth and innovation in life sciences. With our diverse experience and long-term capital commitment from the Nan Fung Group, we are ideally suited to partner with scientists, entrepreneurs, and thought leaders on drug discovery, development, and growth opportunities. Combined with our track record in company formation, venture capital, and investment growth experience, we seek opportunities in long-term value for our investors. Our partnership and direct investment relationship with Pivotal Life Sciences including Pivotal bioVenture Partners US & Pivotal bioVenture Partners China allows us to cover a full spectrum of the life sciences industry, including therapeutics, medical devices and diagnostics across all development stages.
Overview
Location
United States, California, San Francisco
Employees
11-50
Founded date
2017
Investment Type
Venture Capital
Funds raised 1
| Date | Fund size | Announcement |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 27, 2025 | Addition Therapeutics: $100 Million Funding Raised To Advance All-RNA PRINT Platform For One-Time Genomic Medicines | Addition Therapeutics announced it has raised $100 million in financing to date, highlighting progress toward developing one-time genomic medicines for chronic and rare diseases. Based in South San Francisco, the company is building around ... |
| Dec 17, 2025 | Addition Therapeutics Raises $100M in Funding | Addition Therapeutics, a San Francisco, CA-based genomic medicine company, raised $100M in funding. Backers included SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC. The company intends t... |
| Jun 10, 2025 | Mosanna Therapeutics raises USD 80 million to advance sleep apnea nasal spray | Mosanna Therapeutics, the clinical-stage biotech company headquartered in Basel, is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural ai... |
| Jan 14, 2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| Jan 13, 2025 | Windward Bio launches with $200 million Series A financing round | Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| Dec 18, 2023 | Pivotal Life Sciences Closes Pivotal bioVenture Partners Fund II, at $389M | Pivotal Life Sciences, a global investment firm dedicated to investing in companies involved in healthcare innovation seeking to improve patient outcomes, closed Pivotal bioVenture Partners Fund II, at $389m. Fund II will continue Pivotal b... |
Reviews 0
FAQ about Pivotal Life Sciences
When was Pivotal Life Sciences founded?
Pivotal Life Sciences was founded in 2017.
What funds has Pivotal Life Sciences raised?
Pivotal Life Sciences has announced 1 fund on Parsers VC.
What has the press written about Pivotal Life Sciences?
Parsers VC has collected 7 articles mentioning Pivotal Life Sciences, among them “Addition Therapeutics: $100 Million Funding Raised To Advance All-RNA PRINT Platform For One-Time Genomic Medicines” (Dec 27, 2025) and “Addition Therapeutics Raises $100M in Funding” (Dec 17, 2025).
Is Pivotal Life Sciences still active?
Yes, Pivotal Life Sciences is active; its latest activity on Parsers VC dates from May 5, 2026.